Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.
G2/M期激酶的激酶组重编程和MYCN的抑制有助于洛拉替尼在ALK驱动的神经母细胞瘤中发挥更优异的疗效
期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-24-0684
Matkar Smita, East Michael P, Stuhlmiller Timothy J, Witek Gabriela M, Farrel Alvin, Pastor Steven, Okumu Denis O, Kennedy Anne, Kalna Joshua R, Berko Esther R, Casey Colleen E, Krytska Kateryna, Patel Khushbu, Rokita Jo Lynne, Gerelus Mark, Maris John M, Johnson Gary L, Mossé Yael P
